In 2020, Jeffrey S. Hatfield earned $1.35M in total compensation at Larimar Therapeutics, primarily from $221.15K salary. Led Larimar Therapeutics as CEO for 2 years.
Compensation History
Annual executive compensation data for Jeffrey S. Hatfield, including salary, bonuses, and stock awards.
Year
2020
Total Compensation
$1.35M
Salary
$221.15K
Bonus
$0.00
Other
$1.13M
Salary
$221.15KBoard Justification
The compensation philosophy aims to attract, motivate, and retain key executives while aligning their compensation with the interests of stockholders and company performance.
Bonus
$0.00Board Justification
No bonus was paid to Mr. Hatfield for the year 2020 as he ceased employment on May 28, 2020.
Other Compensation
$1.13MBoard Justification
Other compensation includes severance benefits of $1,072,260 and COBRA reimbursement of $58,224.
Restricted Stock
Board Justification
No stock vested in 2020 as all options and stock-based awards were forfeited upon termination of employment.
Performance Metrics
Performance metrics for Mr. Hatfield's compensation were not applicable as he did not receive a bonus or performance-based compensation in 2020.
Jeffrey S. Hatfield
Ex-CEO of Larimar Therapeutics
Education
M.B.A. from The Wharton School, University of Pennsylvania; Bachelor’s degree in Pharmacy from Purdue University.
Sector of Economy
Healthcare
Born
January 1, 1961 - 64 years ago
CEO of Larimar Therapeutics for
2 years 7 months (Oct 2017 - May 2020)
Previous Experience
President and CEO of Vitae Pharmaceuticals; various executive positions at Bristol-Myers Squibb.
Holdings
Track Jeffrey S. Hatfield's stock holdings and portfolio value over time.
Insider Trading
Jeffrey S. Hatfield's recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare Jeffrey S. Hatfield with competitor CEOs and industry peers.